<91E F193FA967B C D B8A7789EF5F8FB4985E8F57315F E696E6464>
|
|
|
- かずゆき たつざわ
- 5 years ago
- Views:
Transcription
1 61716:0017:001 IL SL-1 Glutathione transferases: Old enzymes, new roles 6169:3010:301 SL :4510:451 Cardio-renal effects of cycloxygenase inhibitors: Mechanism of toxicity EL :4511:451 EL :0012:001
2 61617:0018:002 SS-1 SS :3012:002 S1 S1-1 S1-2 S1-3 S1-4 Percellome S1-5 Percellome
3 6169:3012:003 S2 S2-1 1 S2-2 2 S2-3 S :4517:151 S3 / / S3-1 S3-2 S3-3 S3-4 A review of the concordance of toxicity of pharmaceuticals in humans and animals S3-5
4 61614:3017:004 S4 S4-1 S4-2 S4-3 S4-4 S :3012:003 S5Mitochondria-mediated toxicity S5-1 Introduction: Role of mitochondria in drug-induced toxicity S5-2 The mitochondrial permeability transition in apoptotic and necrotic cell death S5-3 Mitochondria-mediated neurotoxicity in Alzheimer's disease S5-4 Evaluation of mitochondrial injury in preclinical safety assessment
5 S5-5 Oxidant-induced mitochondrial permeability transition: Involvement of membrane-bound glutathione transferase 61714:3017:002 S6 S6-1 S6-2 S6-3 FDAICH S6-4 S :0011:302 S7 S7-1 S7-2 S7-3 S7-4
6 61813:4516:152 S8 S8-1 S8-2 Environmental risk assessment of pharmaceuticals in the US/EU - Current regulatory situation and compliance overview S8-3 S8-4 WET S8-5 S :4516:152 W1RNA W1-1 RNAP450 W1-2 RNA EGMERNA W1-3 RNA
7 W1-4 RNA W1-5 RNA 61613:4516:453 W2 W2-1 W2-2 W2-3 MHC W2-4 DNA W2-5 W2-6 AVB 6179:0012:002 W3 W3-1 S6R1
8 W3-2 W3-3 1 W3-4 W :3017:003 W4 ips W4-1 ips ips W4-2 1 W4-3 ES/iPS QT W4-4 Human pluripotent stem cells for toxicology applications -Recent developments in hepatotoxicity-, cardiotoxicity-, and developmental toxicity testing 6189:0011:303 W5 W5-1 in silico in vitroherg W5-2 QT in vivo
9 W5-3 Lolenz plots QT W :0011:301 W6 W6-1 ICH-S9 W6-2 ICH-S91 W6-3 ICH-S92Q&A W6-4 ICH-S9 W :1516:151 W W7-1 W7-2 W7-3
10 2 W7-4 W7-5 W :1515:454 PDIn vitro PD-1 PD-2 PD-3 PD-4 OECD NEDO in vitro in vitrooecd
11 61714:3016:001
12 61713:3014:301 Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy Low dose effects of dichlorodiphenyltrichloroethane (DDT) on gene transcription and DNA methylation in the hypothalamus of young male rats: Implication of hormesis-like effects Catechol estrogens mediated activation of Nrf2 through covalent modification of its quinone metabolite to Keap1 Comprehensive analysis of hepatic gene and protein expression profiles on phenobarbital- or clofibrate-induced hepatic hypertrophy in dogs
13 6169:3011: :3010:15 1. P-71 -III 2. P P-73 p53 4. P-74 HSF1 5. P P P P P P-80 DiclofenacLipopolysaccharide 11. P-81 CYP2C19
14 2 10:1511: P-82 CYP2BHypoxia Inducible Factor P-83 Protection by Ethyl-3, 4-DihydroxybenzoateEDHBagainst cell killing during chemical hypoxia to cultured rat hepatocytes: EDHB prevents free radicals in anoxia Lee Kang Kwang 14. P-84 ips 15. P-85 PDI familyerp29erp P-86 mir-101a 17. P-87 TG 2,3,7,8-TCDD 18. P-88 Cre-loxP 19. P P-90 PXRin vitro 21. P P :0011: P-93 GeneChip 24. P P-95 mrna
15 26. P-96 Constitutive Androstane Receptor 27. P-97 VEGF 28. P-98 Tamoxifen 29. P P P P-102 -NaphthylisothiocyanateANITinterleukin-17IL P :4515: :4514: P-104 LPS 35. P-105 NK CD107a 36. P P P-108 PtIVDNA 39. P-109 ETBEAldh2DNA
16 40. P-110 ICRB6C3F1 41. P-111 ICRB6C3F1 42. P-112 Gpt deltaestragolein vivo 43. P-113 gpt deltaain vivo 44. P :3015: P P P P-118 mrna 49. P-119 CDDPcystatin C 50. P-120 PAHs II 51. P P P P-124
17 :3011:305 10:3011:00 O-1 O-2 Hras128PKC O-3 Ubp3 11:0011:30 O-4 3 H O-5 Gunn4-methylnitrosamino-1-3-pyridyl -1-butanoneNNK O :0011:404 9:009:30 O-7
18 O-8 mirna O-9 PercellomeTCDD3 9:3010:00 O-10 O-11 O-12 10:0010:30 O-13 O-14 C60
19 O-15 C. elegans 10:3010:50 O-16 ASBT O-17 5-p53 10:5011:10 O-18 O-19 11:1011:40 O-20 Indole-3-carbinol O-21 rash2 O-22 MWCNT ERC/mesothelin :3017:104 14:3014:50 O-23 6
20 O-24 14:5015:20 O-25 O-26 ES O-27 PBDE 15:2015:50 O-28 O-29 ES O-30 ES/iPS 15:5016:10 O-31 O-32
21 16:1016:40 O-33 O-34 F344 O-35 NOG 16:4017:10 O-36 in vivo O-37 O-38 CD4 + CD45RB high CD25 - SCID :0011:304 9:009:30 O-39
22 O-40 QT O-41 9:3010:00 O-42 DNA O-43 O-44 Perfluorooctane sulfonate 10:0010:30 O-45 DDT O-46 O-47 10:3011:00 O-48 Nrf1 O-49 6
23 O-50 GluR2NRF-1 11:0011:30 O-51 O-52 AhR O-53
24 61610:00 17:00 P-1 KNADPH: quinone oxidoreductase 1 P-2 P-3 P-4 PB P-5 P-6 P-7 P-8 P-9 PC12 P-10 MethimazolePropylthiouracil
25 P-11 microrna P-12 Quat P-13 P-14 Crl:CDSD P-15 Wistar Hannover P-16 2 P-17 SIRPCD71 P-18 P-19 P-20 P-21
26 P-22 BALB/c P-23 JET P-24 SAMP8: P-25 P-26 MNUrasH2 P-27 P-28 -SHSH test P-29 P-30 P-31 in vitro P-32
27 P-33 ES P-34 ES P-35 CBALLNARIBrdU P-36 P-37 STE P-38 rash2 P-39 Use of toxicogenomic profiling in single-dose studies for predicting the type of liver weight increase P-40 P-41 TGPALT
28 P-42 P-43 P-44 P-45 P-46 DMSO P-47 P-48 P-49
29 P-50 P-51 P-52 TGP P-53 Ethylene Glycol Monomethyl EtherEGME P-54 P-55 SK-Hep-1ethanolFas death receptor P-56 P-57 P-58
30 P-59 P-60 P-61 P-62 P-63 DNA1 P-64 XT-2000iV 2 P-65 P-66
31 P-67 P-68 P-69 P :00 17:00 P-71 -III P-72 P-73 p53 P-74 HSF1 P-75
32 P-76 P-77 P-78 P-79 P-80 DiclofenacLipopolysaccharide P-81 CYP2C19 P-82 CYP2BHypoxia Inducible Factor-1 P-83 Protection by Ethyl-3, 4-Dihydroxybenzoate (EDHB) against cell killing during chemical hypoxia to cultured rat hepatocytes: EDHB prevents free radicals in anoxia
33 P-84 ips P-85 PDI familyerp29erp46a P-86 mir-101a P-87 TG 2,3,7,8-TCDD P-88 Cre-loxP P-89 P-90 PXR in vitro P-91 P-92 P-93 GeneChip
34 P-94 P-95 mrna P-96 Constitutive Androstane Receptor P-97 VEGF P-98 Tamoxifen P-99 P-100 P-101 P-102 -NaphthylisothiocyanateANITinterleukin-17IL-17 P-103 P-104 LPS
35 P-105 NK CD107a P-106 P-107 P-108 PtIVDNA P-109 ETBEAldh2DNA P-110 ICRB6C3F1 P-111 ICRB6C3F1 P-112 Gpt deltaestragolein vivo P-113 gpt deltaain vivo P-114
36 P-115 P-116 P-117 P-118 mrna P-119 CDDPcystatin C P-120 PAHs II P-121 P-122 P P-124
37 P P P P P P-130 2GHz P-131 P-132 NOG P-133 A well-mixed room model for estimating consumer exposure to ingredients used in air refreshener products P-134
38 P-135 BSEPABCB11 P-136 P-137 P-138 P-139 P-140 in vitro P-141 ERKTHP :0015:30 P-142 P-143 /D
39 P-144 P-145 Whole-Body Plethysmography P-146 whole body plethysmography P-147 ERGON-OFF response P-148 P-149 P-150 / P-151 P-152 blonanserin P-153
40 P-154 Reelin P HT1A P-156 MALDI-TOF MS CNS P-157 P-158 QT/QTc P-159 P-160 AVBVerapamilBepridil P-161 P NIBSGottingen P-163 2
41 P-164 P-165 P-166 hoatv1a P P-168 ALT P-169 P-170 microrna P-171 BDF1 P-172 MAP MAP P-173
42 P-174 Assessment of cynomolgus monkey male reproductive parameters in a general toxicology study: Testicular volume, semen analysis and hormone data P-175 EGME RNA P-176 P450 P-177 ETBEALDH2 P-178 Crl:CDSD P-179 Neurokinin receptor antagonist P-180 P-181 In vitro P-182 Diheptyl PhthalateDHPin vivo
43 P-183 P-184 P-185 P-186 GTP P-187 P-188 F344 p,p'-ddt P-189 GC/TOFMS P-190 P-191 P-192 1,2,5,6,9,10- P-193
44 P-194 Microbial Volatile Organic CompoundsTRPA1 TRPV1 P-195 TRPA1TRPV1 P-196 in vivo P-197 P-198 PFOS P-199 A P-200 P mercaptopurinemiRNA P-202 Embryonic Stem Cell Test P-203 Comparing old and new endpoints to assess developmental neurotoxicity: A model study in rats with methylmercury
45 P-204 P-205 First in Human MABEL P-206 FMOPPAR P-207 GHS P P P P P-212 Effects of in utero exposure to di (2-ethylhexyl) phthalate on reproductive development in female offspring P-213 Quantitative recording of spontaneous locomotor activity in socially housed cynomolgus monkeys
t 492 t mg/l 30 mg/l BOD 95 OH = cm 3 / sec 25 8 OH /cm 3 12 = ph ph
2-1 200169 2740 CAS 110-49-6 1103 2- O H 3 C C O CH 2 CH 2 O CH 3 C 5 H 10 O 3 118.13 200168 2-1 99 2-1. 2 2, 3-65 2, 3 144145 45 o.c. 3 392 3 1.512.3 d19 1.009 2 4.07 = 1 30 Pa 0.23 mmhg20 2 4 log Pow0.10
研究成果報告書
21 5 28 2007 2008 CARElk CARPXR CAR CAR EST cdna CAR CAR 10FCS 96 SW480 HepG2 anti-lamin A/C anti-phospho-histone H3 anti-cyclin D1 G1 anti-cyclin A S CAR lamin A/C CAR Fig. 1 Lamin A/C /G1 lamin A/C G1
日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
2
2 3 4 5 6 7 8 9 1 2 3 4 5 10 11 12 1 2 1 2 1 2 13 14 3 17 15 1 2 3 D Usefulness of Tc-99m MIBI SPECT in predicting multidrug resistance gene expression level in non-small cell lung cancer a preliminary
DCHP
2. 2 1. 1) 2) 2 Crj:CD(SD)IGS SPF 0 240 1200 6000 ppm 2 F0 10 F0 10 F1 21 F1 3 10 F1 3 10 F2 21 0 240 1200 6000 ppm 1 F0 0 15.88 79.57 401.8 mg/kg/day F0 0 20.80 104.19 510.7 mg/kg/day F1 0 17.84 89.89
CAS NC(CH 2 ) 4 CN 1,4- C 6 H 8 N c.c d = Pa
1 200117 21512 CAS 111693 110 NC(CH 2 ) 4 CN 1,4- C 6 H 8 N 2 108.14 1 99 2-1. 2 1 295 159 c.c. 550 3 1.7-4.9 20 d 0.965 4 3.73 = 1 0.3 Pa 0.002 mmhg20 2 log Pow-0.32 m/z 41, 1.0 68 0.54 54 0.43 4 Koc9-16
計算機生命科学の基礎II_
Ⅱ 1.4 atsushi_doi@cell-innovator.com 812-8582 3-1-1 8 806 http://www.cell-innovator.com BioGPS Connectivity Map The Cancer Genome Atlas (TCGA); cbioportal GO DAVID, GSEA WCGNA BioGPS http://biogps.org/
untitled
1% 1 mg 1 mg 2 CTD 6 Section 2.6.1 Introduction 2.6.1 H 1 descarboethoxyloratadinesch 34117 7.9 SCH 34117 2.6.1-1 O OC 2 H 5 Cl N N JAN Loratadine (JANINN) ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]
m «É w «Ÿ ÉÉ É É ÉÉ É É
É ÉÉÉÉ ÉÉ Zacc m «É w «Ÿ ÉÉ É É ÉÉ É É É É É É É É É ÉÉ É Uninephrectomy induces Progressive Glomerulosclerosis and Apoptosis in Anti Thy Glomerulonephritis VEGF Gene Expression is Correlated with Glomerular
3, ,104 t mg/l 30 mg/l BOD mg 14 C 8, /kg 11 8, 1 11 OH = cm 3 / sec 11 OH /cm ppm
3, 3-1 200019 4800 CAS 91941 1138 3, 3-4, 4 - -3, 3 - H 2 N Cl Cl NH 2 C 12 H 10 C l2 N 2 253.13 1 95 1. 2 3, 4 132-133 402 5 >200 5 700kg/m 3 5 8.73 = 1 5.610-8 kpa 4.210-7 mmhg20 4 6 log Pow3.51 3.57
サイトメトリー12-1.indd
Cell Growth Inhibition and Apoptosis in Cancer Cells Kazuki Omoteyama, Shoichi Inoue and Alaa-eldin Salah-eldin Department of Environmental Medicine and Informatics, Graduate School of Environmental Earth
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
ミニレビュー
Molecular mechanisms of the suppression of inflammation by thermal stress Ryosuke Takii Department of Biochemistry and Molecular Biology, Yamaguchi University Graduate School of Medicine, Ube 755-8505,
熊本大学学術リポジトリ Kumamoto University Repositor Title 炎症性腸疾患に対する HSF1 及び HSP70 の保護的役割 Author(s) 田中, 健一郎 Citation Issue date Type URL Thesis or Di
熊本大学学術リポジトリ Kumamoto University Repositor Title 炎症性腸疾患に対する HSF1 及び HSP70 の保護的役割 Author(s) 田中, 健一郎 Citation Issue date 2008-03-25 Type URL Thesis or Dissertation http://hdl.handle.net/2298/9448 Right 1
橡96-07.PDF
1 967 2482 CAS 50000 CH 2 O 30.03 2952% 12.5 % 1. 2) -92 2) -19.5 2) 5085 3) 424 3) 7.073.0% 4) 20 d 4 0.815 5) 1.03 ( = 1) 5) 1.33 kpa (10 mmhg) (-88.0) 2) log Pow0.35 ( ) 6) 0.35 ( ) 7) 1) m/z 29 ( 1.0
アミヴィッド静注 CTD 第 2 部 2.1 第 2 部から第 5 部の目次 富士フイルム RI ファーマ株式会社
CTD 第 2 部 富士フイルム RI ファーマ株式会社 ( 空白ページ ) 2 第 2 部 ( モジュール 2): CTD の概要 ( サマリー ) ---------------------------------------------- 第 2 巻 2.2 緒言 2.3 品質に関する概括資料緒言 2.3.S 原薬 (AV-105, ) 2.3.S 原薬 ( フロルベタピル ( 18 F),
20mg CTD 2.4 2.4 2.4... 5 2.4.1... 5 2.4.2... 7 2.4.3... 10 2.4.4... 13 2.4.5... 18 2.4.6... 20 3 2.4 2.4 2.4.1 JNS002 ( HSPC) N-(Carbonyl-methoxypolyethylene glycol 2000)-1,2- distearoyl-sn-glycero-3-phosphoethanolamine
™…{,
16:30-17:40 1-36 1-37 1-38 1-39 1-40 1-41 1-42 33 10:00-11:10 1-43 1-44 1-45 1-46 1-47 1-48 1-49 12:00-12:50 LS4 34 16:30-17:40 1-50 1-51 1-52 1-53 1-54 1-55 1-56 35 16:30-17:40 1-57 1-58 1-59 1-60 1-61
body size no effect mechanical stress GH-IGF1 system + no effect? collagen production of fibroblasts + receptor + + Ia, Ib, II aldosterone renin angiotensin system Mechanical and Endocrinological
化学物質の内分泌かく乱作用に関する環境省の今後の対応方針について
ExTEND2005 2005 3 ExTEND2005 Enhanced Tack on Endocrine Disruption 10 (1998 )5 - SPEED'98-12 (2000 )11 2000 11 ( SPEED'98 ) 14 (2002 )8 (WHO)/ (ILO)/ (UNEP) Global Assessment of the State-of-the-Science
2009年度 東京薬科大学 薬学部 授業計画
2009 2 234 Tokyo University of Pharmacy and Life Sciences since 880 Tokyo University of Pharmacy and Life Sciences Department of Clinical Pharmacy Men's Division Department of Clinical Applied Pharmacy
,309 t 22,069 t 7,240 t µg/l µg/l < ,431-70, , , mg/l m
1 20019 1527 CAS 1317368 1230 PbO 223.20 1 99 1. 2 888 2 9.53 0.017 g/l 20 3 3 2 2. 10 29,309 t 22,069 t 7,240 t 4 1 3. 1 2 3.5 6 1 µg/l 9.1-24 2 µg/l < 43 6 27,431-70,000 4.5-1,300 13.4-17 31.7 0.48-3,459
i 1 2 MCB MCB WCB in vitro CAL in vitro CAL In vitro 5 In vivo
EU ICH ICH i 1 2 MCB 2 3 3 MCB WCB in vitro CAL 3 3 3 in vitro CAL 4 4 4 In vitro 5 In vivo 5 5 5 5 6 9 10 10 11 11 11 ii 11 12 12 13 13 13 14 16 17 17 17 19 1 in vivo BSE BSE DNA in vitro in vivo in vivo
繁殖性に及ぼす影響
5. 2 1. (DEP) 1) DEP 2) 3) 4) DEP 0 600 3000 15000 ppm(0 43 210 1083 mg/kg/day 0 54 261 1336 mg/kg/day ) 24 Crj:CD(SD) IGS 2 DEP 15000 ppm F0 0-21 F1 F0 F1 DEP F1 F1 15000 ppm 15000 ppm F0 F1 F0 F0 P-450
http://www.who.int/ipcs/publications/ehc/en/index.html EHC 1 2 3 4 / EHC http://www.nihs.go.jp/dcbi/publist/ehchsg/ 1-8) WHO/IPCS CICAD (Concise Inter
3 [ ] Priority IARC JMPR 2004 10 Priority 1 Priority 1 Priority 2 Priority 3 Priority 1 1-1) CERI) http://www.cerij.or.jp/ceri_jp/koukai/sheet/sheet_indx4.htm http://www.safe.nite.go.jp/data/sougou/pk_list.html?table_name=hyoka&rank=sh
PowerPoint プレゼンテーション
OECD AOP プロジェクトと免疫毒性 AOP 作成の試み 日本免疫毒性学会試験法委員会 あすか製薬 ( 株 ) 創薬研究本部 久田茂 1 発表内容 化学物質による有害事象発生と AOP OECD による AOP プロジェクト (AOP Programme) カルシニューリン阻害による免疫抑制に関する AOP 作成の事例 まとめ 2 発表内容 化学物質による有害事象発生と AOP OECD による
CHEMOTHERAPY APR. 1984
VOL.32 S-3 CHEMOTHERAPY dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine- CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY Table 1 Implantation rates and post- implantation survival rates in females mated
CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
総括研究成果報告書
BILD 1 diethylstilbestrol (DES) estrogen DNA embryonic stem (ES) ES ES A3-1 ES ES Genetic Microsystems DNA 2 3 DNA DNA DNA BILD ES ES ES RNA RNA cdna DNA DNA estrogen MCF-7 RNA DNA ES mrna Differential
橡アジポニトリル.PDF
1 200117 21512( ) CAS 111693 110( ) 1,4- NC(CH 2 ) 4 CN C 6 H 8 N 2 108.14 1) 99 2-1. 2) 1 2) 295 2) 159(c.c.) 3) 550 3) 1.7-4.9 vol % ( ) 3) d 20 0.965 2) 3.73 ( = 1) 4 0.3 Pa (0.002 mmhg) (20) 2) log
,161 t 9,753 t 2,408 t LC 50 mg/ L EC 50 mg/l * 5 : Selenastrum 6772-h, Sb 2 O 3, : capricornutum 6 3 Selenastrum h, Sb
1 20017 1543 CAS 1309644 125 Sb 2 O 3 291.52 1 99 1. 2 655 1,425 2 2 2 3 5.2 5.67 2 2 2. 10 12,161 t 9,753 t 2,408 t 4 3. 1 2 3 4. LC 50 mg/ L EC 50 mg/l * 5 : Selenastrum 6772-h, Sb 2 O 3, : capricornutum
ナノ材料の有害性評価
CRM CRM 181 TG424 TG42419971995TG407 PBPK PBPK DNA DNA PBPK C C art vein Ramsey & Andersen (1984) ( Qalv Cinh Qt Cvein ) ( Qt Qalv PN ) = + + { ( )} Qi Ci = i Pi ( C ) art Ci dai dt = Qi Qt Pi ( C ) art
9) Reichen J, Paumgartner G: Relationship be- tween bile flow and Na+, K+-Adenosinetriphos- phatase in liver plasma membranes enriched in bile canaliculi. J Clin Invest 60: 429-434, 1977 10) Schaffner
steponeplus_bro_f-0912.indd
StepOnePlus /StepOne PCR PCR PCR StepOnePlus StepOne PCR PCR Features At A Glance StepOne StepOnePlus / 48 96 FAM /SYBR Green dyes VIC /JOE dyes ROX dyes 1. NED /TAMRA dyes VeriFlex Block StepOnePlus StepOne
1 2 D- D- 1206 D- D- -2003 120 /2004 D-FDA GRAS D D- 3 5 5 D- 75 10g/kg 14 40 20 D-101520 90 1520 20%101520 1520 D- 5(D- 2300-6700mg//) () 2024 615 D- 41220g/kg/ 1220g/kg/ 20g/kg/ 1220g/kg/ () 50 D- 10%
(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................
Fig. 1 Mean body weight of pregnant rats administered intravenously with CLM on days 7 to 17 of pregnancy (fetus group) Fig. 2 Mean body weight of female rats administered intravenously with CLM on days
VOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
能書単頁9[1].5(2)
![能書単頁9[1].5(2)](/thumbs/87/96620151.jpg "能書単頁9[1].5(2)")
ips CytoTune -ips ver.1.0 1 I CytoTune ips 3 II 3 3 4 5 III CytoTune ips ips 6 6 6 6 7 1) 2) ips 8 ips 8 SeV 9 SeV 10 IV Q&A 11 V 12 12 VI...13 13...13 2 I CytoTune ips CytoTune ips 4 OCT3/4SOX2 KLF4c
040202PC用.doc
15 48 15 8 25 15 1321 15 8 25 0825002 15 8 25 6 8 15 2 18 15 6 27 2 15 3 13 28 35 (1) 51 198 7 (2) 3 6 1 100g (1) 1 (1) 1 2 1 astaxanthin;3,3 -dihydroxy-, -carotene-4,4 -dione (2) 1 2 C40H52O4 596.86 97.0
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
資料１(目消し版).ppt
1 Dr. Grandjean 2 15 45 3 4 CH 3 Hg + Hg 0 fi Hg ++ fich 3 + MeHg MeHg 5 Methylmercury-2 6 :, A. Yasutake 7 - A. Yasutake 8 :,. A. Yasutake 9 A. Yasutake 10 (%) : : : : : MeHg 0.05 250 : 2 : 1 : 0.1 :
BRC 61
BRC 61 JF1 F1 LDH 62 (Macaca fascicularis) DBA/2 ddy BDF1 C57BL/6 B6 TG BDF1 C57BL/6 Publications 1.Itoh M., Matsuda J., Suzuki O., Ogura A., Oshima A., Tai T., Suzuki Y. and Takashima S.: "Development
S-5 1, ランチョンセミナー 1 第 1 日目 6 月 2 日 ( 金 ) 12:00 ~ 13:00 第 1 会場 Nuclear transfer for rejuvenation of human oocytes: where we are and wherea
第 58 回日本卵子学会プログラム 特別講演 1 第 1 日目 6 月 2 日 ( 金 ) 13:10 ~ 13:50 第 1 会場 特別講演 2 第 1 日目 6 月 2 日 ( 金 ) 14:00 ~ 14:40 第 1 会場 1 1, 2 2 3 4 1 2 3 4 教育講演 1 第 1 日目 6 月 2 日 ( 金 ) 14:50 ~ 15:30 第 1 会場 教育講演 2 第 1 日目 6
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
-1 - -2 - -3 - -4 - -5 - -6 - -7 - -8 - -9 - - 10 - -11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 - - 31 - - 32
9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00
9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00 ポスターについて 1. ポスター 貼 付 用 の 展 示 ボードは 縦 180 横 90cm の 大 きさです 2. 演 題 名 発 表 者 名 所 属 を 明 記 したもの(20 70cm) をご 用 意 ください 実 際 使 用 できるスペースは 155
第１部 一般的コメント
(( 2000 11 24 2003 12 31 3122 94 2332 508 26 a () () i ii iii iv (i) (ii) (i) (ii) (iii) (iv) (a) (b)(c)(d) a) / (i) (ii) (iii) (iv) 1996 7 1996 12
橡三酸化二アンチモン.PDF
1 2001 7 1 543( ) CAS 1309 64 4 1 25 ( ) Sb 2 O 3 291.52 1) 99 1. 2) 655 3) 1,425 3) ( ) 2) ( ) 2) ( ) 2) 5.2 ( ) 5.67 ( ) 3) 2) 2. 10 12,161 t ( 9,753 t 2,408 t) 4 2 1) 3. 1) 2) 3) 4. Selenastrum capricornutum
CAS O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) % 2- A BHT , 4
2-1 9628 31307 CAS 117817 2- O C O * DOP* DEHP 2- C O O * n- C 24 H 38 O 4 390.56 CH 2 CH 2 CH 2 CH 3 CH (CH 2 ) 3 1 99 % 2- ABHT 1. 2-55 3 3, 4 386 171 350 6 0.1 % d 20 4 0.9861 4 13.48 0.30410-4 Pa 2.2810-7
Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
第１章 国民年金における無年金
1 2 3 4 ILO ILO 5 i ii 6 7 8 9 10 ( ) 3 2 ( ) 3 2 2 2 11 20 60 12 1 2 3 4 5 6 7 8 9 10 11 12 13 13 14 15 16 17 14 15 8 16 2003 1 17 18 iii 19 iv 20 21 22 23 24 25 ,,, 26 27 28 29 30 (1) (2) (3) 31 1 20
表1票4.qx4
iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614
untitled
... 4...5...6...7...10...11... 12...12...12...13...14...15...15...16...16...17...17...18...18...19...19...19 Hill...20...20...21...21...22...23...24...25... 34...34...35...38-2 - ...41...49...51...51...51...52...53...56...56...57...60...60-3
橡99-24_00 アリルアルコール.PDF
1 9924 2260 CAS 107186 H 2 C CH CH 2 OH 2- -1- C 3 H 6 O 58.08 1 99 1. 2, 3 3, 4, 5-129 96-97 2 21c.c. 24o.c. 2 6, 7 378 6, 7 2.5-18 d 20 4 0.8540 2, 5 2.00 = 1 2.7 kpa 20 mmhg204.3 kpa 32 mmhg30 4 log
( ( ( (
2005 11 1...- 1-2...- 6-2.1...- 6-2.2...- 6-3...- 7-4...- 9-4.1...- 9-4.2...- 15 - (1...- 16 - (2...- 17 - (3...- 18 - (4...- 19-5...- 20 - 1 A ( BPA 1961 2003 40 (p.5 9 ( PC ( EX BPA PC CD DVD OA EX BPA
soturon.dvi
12 Exploration Method of Various Routes with Genetic Algorithm 1010369 2001 2 5 ( Genetic Algorithm: GA ) GA 2 3 Dijkstra Dijkstra i Abstract Exploration Method of Various Routes with Genetic Algorithm
steponeplus_bro_f-0210.indd
StepOnePlus / StepOne PCR PCR Applied Biosystems StepOnePlus StepOne PCR 1 Features At A Glance StepOne StepOnePlus / 48 96 FAM/SYBR Green dyes VIC/JOE dyes ROX dyes NED/TAMRA dyes 1. VeriFlex Block StepOnePlus
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
Isotope News 2017年10月号 No.753
Ishioka Noriko ₁ はじめに RI RI RI RI ₂ 悪性褐色細胞腫と治療の現状 3,000 90 I meta- Iiodo-benzylguanidine I-MIBG 1 ₃ α 線の標的アイソトープ治療 2016 6 223 RaCl2 223 Ra 223 Ra 14 表 1 α 線と β 線の違い -decay (42%) Eα = 5.9 MeV At 7.2 h EC
3 光毒性第三者評価報告書100924改
21 5 13 22 5 17 1 2 in vivo 24 in vivo 9 6 6 GLP 1 b 4 Acridine BMDM 4-t-butyl-4-methoxydibenzoylmethane CHD Chlorhexidine Bithionol CHD Bithionol in vivo in vivo b in vivo 70% b 5 in vitro 3T3-NRU 4 9
3 6 6 8 5 5 0 4 3 4 4 0,000 3 ID ID ID 4 7 9 :5 4 5 60-8048 NACOS TEL: 075-45-366 FAX: 075-45-366 E-mail: jiao@nacos.com 3. Power Point PC 0 5. Power Point PC 7 3 3. 3 5 PC PC PC Windows Power Point USB
VOL.40 S-1
238 CHEMOTHERAPY APRIL 1992 Russell A.W. EFreeman S.J. ESiddall R.A. ICI Pharmaceuticals Safety of Medicines Department** **Alderley Park, Macclesfield Cheshire, SK10 4TG, England VOL.40 S-1 240 CHEMOTHERAPY
研究成果報告書
系 レニン 1. Ito D, Ito O, Mori N, Suda C, Hao K, Cao P, Muroya Y, Takashima K, Shimokawa H, Kohzuki M. Exercise training upregulates nitric oxide synthases in the kidney of rats with chronic heart failure.
untitled
ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504
橡災害.PDF
1 2 3 4 5 6 7 8 9 10 11 12 2.1 2.2 2.2.1 13 2.2.2 2.2.3 14 2.3 2.3.1 2.3.2 all or nothing 2.4. 2.4.1 15 i) ii) iii) iv) 2.5 2.4.2 2.2 2.5 2.5.1 16 2.5.2 2.6 2.6.1 2.4 2.6.2 2.6.3 2.6.4 17 18 3.2.1 Hazard
Corning w In vivo w w w in vivo Create a More Natural Environment for Your Cells Costar ready-to-use 25 Falcon Corning BioCoat Falcon Corning BioCoat
Permeable Supports Selection Guide Transwell Falcon Corning w In vivo w w w in vivo Create a More Natural Environment for Your Cells Costar ready-to-use 25 Falcon Corning BioCoat Falcon Corning BioCoat
第79回_プログラム.indd
Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial
研究成果報告書
COE 8 4 月 13 3 17-19,20-22 -COO - NH4 + 7 Fig.1 た 2 プ Fig.1 =0.154mol/L =0.1ml/min = 0.665g=20 PET AA PET Fig.2 AA AA PET PET AA Fig.2 PET AA-graft PET (3.17%, 6.37%) Fig.3 Fig.4 14 RDSv/h=1.10*e (-0.055d)
o 2o 3o 3 1. I o 3. 1o 2o 31. I 3o PDF Adobe Reader 4o 2 1o I 2o 3o 4o 5o 6o 7o 2197/ o 1o 1 1o
78 2 78... 2 22201011... 4... 9... 7... 29 1 1214 2 7 1 8 2 2 3 1 2 1o 2o 3o 3 1. I 1124 4o 3. 1o 2o 31. I 3o PDF Adobe Reader 4o 2 1o 72 1. I 2o 3o 4o 5o 6o 7o 2197/6 9. 9 8o 1o 1 1o 2o / 3o 4o 5o 6o
(1) Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M and Kuroda M: The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,
CHEMOTHERAPY
CHEMOTHERAPY Fig.1 Effect of 6059-S on body weight changes in male rats Table 1 Effect of 6059-S on body weight changes in female rats :Mean }S.E. Table 2 Reproductive findings of rats treated with 6059
15K00827 研究成果報告書
(TG) TG sterol regulatory element- binding protein (SREBP)-1c (Diabetes 53:560-569, 2004) SREBP-1c (1) SREBP-1c SREBP-1c liver X receptor (LXR)LXR O-Glc NAc (O-linked -N-acetyl glucosamine) (J Biol Chem
日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
Microsoft Word - web.docx
12 10 E 16:30 17:30 : ( ) " " ( ) 12 10 15:50 16:20 A 1 ( ) ( ) B ( ) ( ) D ( ) ( 12 11 B 10:00 12:00 " " ( ) ( ) 2 (10 ) A 1 ( ) 8:30 12:40 8:30 9:20 1 ( ) 1A-01 Cannabidiol-2',6'-dimethyl ether ( 1,
CHEMOTHERAPY NOV. 1990
VOL.38 S-2 6, 8- Difluoro- 1-(2- fluoroethyl)- 1, 4- dihydro- 7-(4- methyl- 1- piperazinyl)- 4- oxo- 3- quinolinecarboxylic CHEMOTHERAPY NOV. 1990 VOL.38 S-2 Fig. 1. Body weight changes of male rats treated
Ⅰ. Statistics Concerning Health Birthweight (1) Birthweight by year (2) Mean birthweight by prefecture, 2007-1997 (3) Percentage of births under 2,500g by prefecture, 2007-1997 Sex Ratio (4) Sex ratio
The Japanese Journal of Health Psychology, 29(S): (2017)
Journal of Health Psychology Research 2017, Vol. 29, Special issue, 139 149Journal of Health Psychology Research 2016, J-STAGE Vol. Advance 29, Special publication issue, 139 149 date : 5 December, 2016
J. Soc. Cosmet. Chem. Jpn. 7-chome, Edogawa-ku, Tokyo 132, Japan 2.1 J. Soc. Cosmet. Chem. Japan. Vol. 31, No
J. Soc. Cosmet. Chem. Jpn. 7-chome, Edogawa-ku, Tokyo 132, Japan 2.1 J. Soc. Cosmet. Chem. Japan. Vol. 31, No. 2 1997 167 Fig.-1 Balanced fiber method Fig.-2 The effects of perming and IG on breaking off
< > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ [ [ [ [ KULASIS
< > Introduction to Basic Organic Chemistry 1,2 [ 2 [ 10 11 12 13 14 15 [ [ [ [ KULASIS < > Introduction to Basic Physical Chemistry 1,2 2 [ advanced [ 11 12 14 15 [ [ [ [ KULASIS < > Introduction to Basic